首页> 中国专利> 用于检测ddcfDNA的产品在制备检测肺部感染引起的移植肾损伤和预后中的用途

用于检测ddcfDNA的产品在制备检测肺部感染引起的移植肾损伤和预后中的用途

页面导航

摘要
著录项
法律信息
相似文献

摘要

本发明提供了一种用于检测ddcfDNA的产品在制备检测肺部感染引起的移植肾损伤和预后的产品中的用途，用于检测肺部感染引起的移植肾损伤和预后效果评估的产品，以及检测肺部感染对移植肾损伤和预后效果评估的方法，所述的用于检测ddcfDNA的产品可以检测肾移植受者血浆中供体游离cfDNA(ddcfDNA)的水平，根据供体游离cfDNA(ddcfDNA)的水平诊断肺部感染对移植肾功能损伤和预后效果评估，能够实现对器官移植受者术后的肺部感染对移植肾损伤和预后早期诊断，具有快速、准确、灵敏度高的优势，且检测方法无创，极大减少患者痛苦。

著录项

公开/公告号CN110452975A

专利类型发明专利
公开/公告日2019-11-15

原文格式PDF
申请/专利权人上海奥根诊断技术有限公司;
展开▼

申请/专利号CN201910587416.0
发明设计人蒋廷亚;刘海涛;葛军;刘枫;王啸晨;黎小锋;
展开▼

申请日2019-06-28
分类号
代理机构北京三聚阳光知识产权代理有限公司;
代理人谢楠
地址 201100上海市闵行区新骏环路760号1幢401室
入库时间 2024-02-19 14:44:26

法律信息

法律状态公告日

法律状态信息

法律状态
2019-12-10

实质审查的生效 IPC(主分类):C12Q1/6883 申请日:20190628

实质审查的生效
2019-11-15

公开

公开

相似文献

专利
中文文献
外文文献

1. 用于检测ddcfDNA的产品在制备检测肺部感染引起的移植肾损伤和预后中的用途 [P] . 中国专利： CN110452975A . 2019-11-15
2. mtDNA检测试剂在制备供肾损伤程度或移植肾功能的诊断试剂盒中的用途及诊断试剂盒 [P] . 中国专利： CN108342470A . 2018-07-31
3. Use of product comprising catuama extract as an antioxidant or cerebral vasodilating agent, pharmaceutical composition comprising such product for the prophylaxis or treatment of vascular disorders and disorders caused by the improper presence of free radicals, method for the prophylaxis or treatment of cerebral vascular disorders and disorders caused by improper pressing of free radicals using said product and use of said product for the production of a pharmaceutical composition, for the prophylaxis or treatment of vascular disorders and disorders caused by the improper presence of free radicals [P] . BR0102185A . 2003-02-18

机译：包含catuama提取物作为抗氧化剂或脑血管舒张剂的产品的用途，包含该产品的药物组合物用于预防或治疗由自由基的不当存在引起的血管疾病和病症，预防或治疗脑血管疾病和病症的方法由于使用所述产品不当按压自由基而导致的疾病，以及所述产品在制备药物组合物中的用途，所述药物组合物用于预防或治疗血管疾病和由自由基的不当存在引起的疾病
4. Process of preparation of an antigen derived from a microorganism that causes infectious and / or parasitic disease Process of preparation of an antigen from T cruzi antigen derived from a microorganism that causes infectious disease and / or parasitic antigen derived from T cruzi that causes Chagas disease composition the base of an antigen derived from microorganism that causes infectious and / or parasitic disease composition the base of antigen from T cruzi use of the antigen derived from microorganism that causes infectious and / or parasitic disease in serological tests and vaccines use of antigen derived from T cruzi cause of chagas disease in serological tests and vaccines process for detecting antibodies against microorganism antigen causing infectious and / or parasitic disease and confirmatory serodiagnosis kit for infectious and / or parasitic disease [P] . BR9503451A . 1997-09-30

机译：源自引起传染性和/或寄生虫病的微生物的抗原的制备过程由源自引起传染性疾病的微生物的T克鲁兹抗原的抗原和/或引起恰加斯病组合物的源自T cruzi的寄生虫抗原的制备过程源自引起感染和/或寄生虫病的微生物的抗原的成分组成来自T cruzi的抗原的碱基在血清学测试和疫苗中使用源自引起感染和/或寄生虫病的微生物的抗原的用途血清学测试和疫苗过程中查加斯病的克鲁斯病因，用于检测针对引起传染病和/或寄生虫病的微生物抗原的抗体，以及传染病和/或寄生虫病的确诊血清诊断试剂盒
5. Protein isolated and htrt preparation, htrt protein fragment, human telomerase, isolated polynucleotide, expression vector, cell, non-human organism, isolated or recombinant antibody, processes for determining whether a compound or treatment is a modulator of an activity or expression of htrt, if a test compound is a modulator of a telomerase reverse transcriptase activity, to identify a compound that modulates htrt activity, to prepare recombinant telomerase, to detect a htrt people product in a sample and the presence of at least one telomerase positive human cell in a biological sample, to diagnose a telomerase-related condition in a patient and cancer to provide a prognosis for a cancer patient, to monitor the ability of an anti-cancer treatment, to reduce the ability proliferation of cancer cells in a patient, to increase the proliferative capacity of a vertebrate cell, to treat a condition associated with a high level of telomerase activity within a cell, to isolate a selected nu [P] . BR9712254A . 2000-01-18

机译：分离的蛋白和htrt制剂，htrt蛋白片段，人类端粒酶，分离的多核苷酸，表达载体，细胞，非人类有机体，分离的或重组抗体，确定化合物或治疗是否是htrt活性或表达调节剂的过程，如果受试化合物是端粒酶逆转录酶活性的调节剂，则鉴定可调节htrt活性的化合物，制备重组端粒酶，检测样品中的htrt人产物以及是否存在至少一个端粒酶阳性人类细胞生物学样品，以诊断患者和癌症中的端粒酶相关病症，为癌症患者提供预后，以监测抗癌治疗的能力，减少患者癌细胞的增殖能力，从而增加癌症患者的预后。脊椎动物细胞的增殖能力，用于治疗与细胞内端粒酶活性高水平有关的疾病，分离选定的核酸